Servier Germany

What Servier Germany does

Servier Deutschland GmbH is the German commercial subsidiary of the Servier Group, an independent international pharmaceutical company governed by a private foundation (LES LABORATOIRES SERVIER) since 2014. Headquartered in Munich (Elsenheimerstraße 53, 80687 München), the German entity was founded in 1996 and operates alongside a separate Munich-based R&D subsidiary, Servier Forschung und Pharma-Entwicklung GmbH (founded 1985), which functions as Servier's Hub Europe for clinical research across the DACH region and Benelux. Servier Germany markets approximately 20 branded originator pharmaceutical products across two principal therapeutic areas: cardiovascular and metabolic diseases (hypertension, heart failure, type 2 diabetes, depression) and — its strategic growth engine — Hematology/Oncology, which generates roughly 90% of German revenues. The oncology portfolio includes first-in-class and differentiated assets such as Voranigo (vorasidenib, EU-approved September 2025 as the first new targeted therapy for IDH-mutated gliomas in ~25 years), Tibsovo (ivosidenib), Oncaspar (pegaspargase), Onivyde (liposomal irinotecan), and Lonsurf (trifluridine/tipiracil).

The commercial model is an enterprise field-sales and direct-distribution motion: Servier Germany reaches healthcare professionals and hospitals through medical science liaisons and a gated Fachkreise portal (fachkreise.servier.de) with e-learning and training certifications, while pharmacies order directly via a structured email channel ([email protected]) with 1–3 business day delivery, SEPA direct debit, and 0.5% Skonto for 14-day payment (or 45 days net). Pricing is regulated via the German reference pricing system (Festbeträge) and is not publicly disclosed. The German subsidiary is the third-largest and fastest-growing country entity within the Servier Group, which itself generated EUR 6.9 billion in FY 2024/2025 across 130+ countries with over 20,000 employees and ~20% of brand-name revenues reinvested into R&D.

Servier Germany's parent group pursues a deliberate rare-disease strategy enabled by foundation ownership, supporting long-cycle R&D for high-unmet-need indications in oncology and, increasingly, neurology. Recent group-level strategic moves include the EUR 200M Servier Venture Fund (launched January 2026), the announced USD 2.5B acquisition of Day One Biopharmaceuticals (March 2026), and the announced up-to-USD 2.65B acquisition of Edgewise Therapeutics' muscular dystrophy business (June 2026). Digital channels include the GI 4.0 electronic package leaflet platform (QR-code, web, iOS, Android), the MyServier professional portal, disease-education websites, and the annual i-care-Award for digital nursing innovations. The company also maintains a strong industry-association footprint, with the German Managing Director Oliver Kirst serving as Chairman of the Bundesverband der Pharmazeutischen Industrie (BPI) since November 2023.

Name

Servier Germany

Legal name

Servier Deutschland GmbH

Website

https://servier.de

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

51–100 employees

Short description

Servier Deutschland GmbH is the Munich-based German commercial subsidiary of the Servier Group, marketing approximately 20 branded originator pharmaceuticals — primarily rare-disease hematology and oncology therapies (Voranigo, Tibsovo, Oncaspar, Onivyde, Lonsurf) plus cardiovascular and metabolic products — to physicians, hospitals, and pharmacies across Germany via field sales, a dedicated HCP portal, and direct pharmacy distribution.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Prescription pharmaceuticals
• Cardiovascular medicines
• Oncology therapies
• Hematology drugs
• Specialty pharmaceuticals

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Pharmaceutical Product Sales (Germany): Servier Germany generates revenues by selling innovative therapies primarily in the areas of Hematology/Oncology (~90% of revenues) and cardiovascular/metabolic diseases to healthcare providers, hospitals, and pharmacies across Germany. The company sells approximately 20 pharmaceutical products covering hypertension, oncology, and other therapeutic areas. Distribution is handled through direct pharmacy orders (email-based) and healthcare professional detailing. The German subsidiary is the third-largest and fastest-growing country entity within the Servier Group.
2. Pharmaceutical Product Sales (Global Group): The global Servier Group generated EUR 6.9 billion in revenues in FY 2024/2025 across more than 130 countries from sales of branded pharmaceutical products. Approximately one-third of global revenues come from Hematology/Oncology. Servier reinvests ~20% of brand-name pharmaceutical revenues into R&D. The company operates as a private foundation with no external shareholders, reinvesting all profits into R&D and new therapies.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Core offering

Servier Deutschland GmbH markets and distributes branded originator prescription pharmaceutical products in Germany, with approximately 90% of revenues derived from hematology/oncology therapies (Tibsovo, Voranigo, Oncaspar, Onivyde, Lonsurf) and the remainder from its historic cardiometabolism franchise (BiPreterax N, Coversum Arginin, Diamicron, Natrilix SR, Procoralan, Valdoxan, among others). The company operates a direct pharmacy order channel (email-based with SEPA terms), a gated healthcare professional portal (Fachkreise), and supplements its medicines with digital services such as the GI 4.0 electronic package leaflet platform and the MyServier HCP portal.

Product overview

Servier Germany operates a diversified pharmaceutical portfolio comprising two main product categories: (1) branded originator medications across cardiovascular/metabolic disorders and hematology/oncology, and (2) digital health platforms. In cardiovascular/metabolic care, the portfolio includes antihypertensives such as BiPreterax N, Preterax N, Coversum Arginin, Natrilix SR, Natrixam, Triveram, Viacoram, Viacorind, and Procoralan, along with the antidiabetic Diamicron and the CNS agent Valdoxan. The oncology portfolio — the strategic growth engine following a series of acquisitions — includes Oncaspar (for acute lymphoblastic leukemia), Onivyde (pancreatic cancer), Lonsurf (colorectal cancer), Tibsovo (IDH1-mutated cancers), and VORANIGO (IDH-mutated gliomas, the 2025 EU-approved therapy representing the first new targeted treatment for certain brain tumors in ~25 years). The digital layer consists of the GI 4.0 electronic package leaflet platform (accessible via web, iOS, and Android) and the MyServier professional portal for healthcare practitioners.

Differentiator

Problem solved

Functional benefit

Brands

• GI 4.0: Digital package information service providing digital access to drug information via app and website, launched 2016 as a pilot project by a consortium of pharmaceutical companies.

Products and services

• BiPreterax N Combination antihypertensive medication combining perindopril and indapamide for the treatment of hypertension; available in standard and forte formulations for physicians and pharmacies in Germany.
• Coversum Arginin ACE inhibitor (perindopril arginine) for the treatment of hypertension and cardiovascular conditions; available in 2.5 mg, 5 mg, and 10 mg dosages.
• Diamicron Sulfonylurea antidiabetic medication (gliclazide) for the treatment of type 2 diabetes mellitus.
• Lonsurf Antimetabolic oncology medication (trifluridine/tipiracil) for the treatment of metastatic colorectal cancer; used as monotherapy or in combination with bevacizumab and studied in the SUNLIGHT and SOLSTICE Phase III trials.
• Natrilix SR Sustained-release indapamide antihypertensive medication for the treatment of essential arterial hypertension.
• Natrixam Combination antihypertensive medication combining indapamide with amlodipine in a single tablet for the treatment of essential hypertension.
• Oncaspar Pegylated asparaginase (pegaspargase) for the treatment of acute lymphoblastic leukemia (ALL); a key component of pediatric and adult ALL regimens.
• Onivyde Liposomal irinotecan formulation for the treatment of metastatic pancreatic adenocarcinoma in combination with 5-fluorouracil and leucovorin in patients previously treated with gemcitabine-based therapy.
• Preterax N Combination antihypertensive medication combining perindopril and indapamide for the treatment of hypertension.
• Procoralan Ivabradine medication for the treatment of chronic heart failure and symptomatic stable angina pectoris in patients with elevated heart rate.
• Tibsovo Targeted oncology therapy (ivosidenib) for the treatment of IDH1-mutated cancers, including acute myeloid leukemia (AML) and IDH1-mutated cholangiocarcinoma; subject to authorized training material including a patient card.
• Triveram Combination antihypertensive medication combining atorvastatin with perindopril and amlodipine for the treatment of essential hypertension.
• Valdoxan Melatonin receptor agonist (agomelatine) for the treatment of major depressive episodes in adults, acting through a novel mechanism targeting melatonin and serotonin receptors.
• Viacoram Combination antihypertensive medication combining amlodipine with sacubitril/valsartan for the treatment of hypertension.
• Viacorind Combination antihypertensive medication combining amlodipine with sacubitril/valsartan for the treatment of essential hypertension.
• VORANIGO Targeted oncology therapy (vorasidenib) for the treatment of IDH-mutated gliomas, representing a new therapeutic option in this indication and the first new targeted therapy approved in approximately 25 years.
• GI 4.0 (Gebrauchsinformation 4.0) Digital platform providing electronic package leaflets (ePI) for all Servier products, accessible via QR code on medication packaging, a dedicated website (gebrauchsinformation4-0.de), and mobile apps on the Apple App Store and Google Play Store; features include keyword search, adjustable text size, read-aloud function for visually impaired users, and automatic safety information updates.
• MyServier Platform Secure, password-protected digital platform for healthcare professionals (HCPs) providing product information, e-learning modules, training certificates, scientific event recordings, and medical communications; access requires professional credentials verification and supports SSO, restricted to verified medical professionals per German Heil- und Hilfsmittelversorgungsgesetz (HWG) §10.

Quantifiable outcome

• EUR 6.9 billion in global revenues (FY 2024/2025), with approximately one-third from Hematology/Oncology
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability9 records

Feature3 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Edgewise Therapeutics (USA)coreStrategic or Co-development Partner · 1 June 2026Servier announced acquisition of Edgewise Therapeutics' muscular dystrophy business in June 2026 for up to USD 2.65 billion (USD 1.55 billion upfront + up to USD 1.1 billion in milestones). The acquisition includes sevasemten, an investigational fast skeletal myosin inhibitor for Becker and Duchenne muscular dystrophies, supporting Servier's expansion into rare neurology.
• Day One Biopharmaceuticals (USA)coreStrategic or Co-development Partner · 10 March 2026Servier announced the acquisition of Day One Biopharmaceuticals in March 2026, with formal takeover in April 2026 for approximately USD 2.5 billion. Day One has an approved therapy for a specific form of brain tumors in children in the USA and develops additional treatments for rare cancers. The acquisition expands Servier's R&D pipeline across all development phases from preclinical to Phase 3.
• AKG e.V. (Arzneimittel und Kooperation im Gesundheitswesen)coreStrategic or Co-development Partner · 1 November 2025Servier Germany is an active member of AKG e.V. and has been awarded the AKG Compliance Seal repeatedly (most recently November 2025). Anne-Katrin Saubiez serves as Deputy Chair of AKG's Board since 2021. The AKG transparency code requires annual disclosure of financial transfers to healthcare professionals and patient organizations.
• Deutscher Pflegetag Servicegesellschaft mbH (DPSG)minorGTM or Marketing Partner · 1 January 2025Servier partners with DPSG (German Nursing Day Service Company) for the annual i-care-Award, presented during the Deutscher Pflegetag conference in Berlin. The award recognizes digital innovations supporting nursing care professionals.
• 16 Startup Companies (Paris-Saclay Incubator)minorStrategic or Co-development Partner · 1 May 2023Servier's startup incubator at the Paris-Saclay Innovation Center (opened May 2023) currently houses 16 startups providing an integrated research environment with access to laboratories, mentoring, and scientific exchange. This model enables Servier early access to new scientific approaches, technologies, and promising projects in early drug discovery.
• Agios Pharmaceuticals (USA)coreStrategic or Co-development Partner · 1 January 2021Servier acquired the oncology business of Agios Pharmaceuticals in 2021, expanding its oncology portfolio and capabilities, particularly in IDH inhibitors (Tibsovo). The acquisition also included the opening of Servier's R&D center in Boston, USA.
• Symphogen (Denmark)coreStrategic or Co-development Partner · 1 January 2020Servier acquired Danish antibody research company Symphogen in 2020, strengthening its R&D pipeline in antibody-based immuno-oncology. The acquisition established an R&D center in Copenhagen, enhancing Servier's capabilities in antibody therapeutics and expanding the company's biologics platform.
• PharmaFakten (German Pharmaceutical Industry Initiative)minorGTM or Marketing Partner · 1 January 2019Servier participates in PharmaFakten, an initiative of pharmaceutical manufacturers in Germany communicating about health, innovation, and prosperity. The initiative publishes flyers and educational materials about the research-based pharmaceutical industry.
• Shire (Takeda) – Oncology BusinesscoreStrategic or Co-development Partner · 1 January 2018Servier acquired Shire's oncology business in 2018, which included Oncaspar and other oncology products. This acquisition marked Servier's entry into the US and Japanese markets through the establishment of new commercial subsidiaries.
• Rote Liste Service GmbH (Germany)coreTechnology or Integration · 1 January 2016Rote Liste Service GmbH is the operator of the GI 4.0 digital package leaflet platform. Servier participates in this consortium along with other pharmaceutical companies, pharmaceutical industry associations, patient groups, and pharmacy associations, with regulatory support from BfArM and PEI. The platform provides digital access to package leaflets via QR code scanning.

Scale indicators12 records

Recent moves13 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/servier?lang=fr
• Facebookfacebook.com/Servier
• LinkedInlinkedin.com/company/servier-deutschland

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Servier Germany